National Institute on Aging; Notice of Meeting, 74647-74648 [2022-26467]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 233 / Tuesday, December 6, 2022 / Notices
www.hhs.gov/conscience/religiousfreedom/.
lotter on DSK11XQN23PROD with NOTICES1
E. Federal Awardee Performance and
Integrity Information System (FAPIIS)
The IHS is required to review and
consider any information about the
applicant that is in the FAPIIS at
https://www.fapiis.gov/fapiis/#/home
before making any award in excess of
the simplified acquisition threshold
(currently $250,000) over the period of
performance. An applicant may review
and comment on any information about
itself that a Federal awarding agency
previously entered. The IHS will
consider any comments by the
applicant, in addition to other
information in FAPIIS, in making a
judgment about the applicant’s integrity,
business ethics, and record of
performance under Federal awards
when completing the review of risk
posed by applicants as described in 45
CFR 75.205.
As required by 45 CFR part 75
Appendix XII of the Uniform Guidance,
NFEs are required to disclose in FAPIIS
any information about criminal, civil,
and administrative proceedings, and/or
affirm that there is no new information
to provide. This applies to NFEs that
receive Federal awards (currently active
grants, cooperative agreements, and
procurement contracts) greater than $10
million for any period of time during
the period of performance of an award/
project.
Mandatory Disclosure Requirements
As required by 2 CFR part 200 of the
Uniform Guidance, and the HHS
implementing regulations at 45 CFR part
75, the IHS must require an NFE or an
applicant for a Federal award to
disclose, in a timely manner, in writing
to the IHS or pass-through entity all
violations of Federal criminal law
involving fraud, bribery, or gratuity
violations potentially affecting the
Federal award.
All applicants and recipients must
disclose in writing, in a timely manner,
to the IHS and to the HHS OIG all
information related to violations of
Federal criminal law involving fraud,
bribery, or gratuity violations
potentially affecting the Federal award.
45 CFR 75.113.
Disclosures must be sent in writing to:
U.S. Department of Health and Human
Services, Indian Health Service,
Division of Grants Management, Attn:
Marsha Brookins, Director, 5600 Fishers
Lane, Mail Stop: 09E70, Rockville, MD
20857, (Include ‘‘Mandatory Grant
Disclosures’’ in subject line), Office:
(301) 443–4750, Fax: (301) 594–0899,
email: DGM@ihs.gov and U.S.
VerDate Sep<11>2014
17:51 Dec 05, 2022
Jkt 259001
Department of Health and Human
Services, Office of Inspector General,
Attn: Mandatory Grant Disclosures,
Intake Coordinator, 330 Independence
Avenue SW, Cohen Building, Room
5527, Washington, DC 20201, URL:
https://oig.hhs.gov/fraud/report-fraud/,
(Include ‘‘Mandatory Grant Disclosures’’
in subject line), Fax: (202) 205–0604
(Include ‘‘Mandatory Grant Disclosures’’
in subject line) or email:
MandatoryGranteeDisclosures@
oig.hhs.gov.
Failure to make required disclosures
can result in any of the remedies
described in 45 CFR 75.371 Remedies
for noncompliance, including
suspension or debarment (see 2 CFR
part 180 and 2 CFR part 376).
VII. Agency Contacts
1. Questions on the programmatic
issues may be directed to: Terri
Schmidt, Director, Office of Direct
Service and Contracting Tribes, Indian
Health Service, 5600 Fishers Lane, Mail
Stop: 08E17, Rockville, MD 20857,
Phone: (301) 443–1104, email:
terri.schmidt@ihs.gov.
2. Questions on grants management
and fiscal matters may be directed to:
Sheila A.L. Miller, Grants Management
Specialist, Indian Health Service,
Division of Grants Management, 5600
Fishers Lane, Mail Stop: 09E70,
Rockville, MD 20857, Phone: (240) 535–
9308, email: sheila.miller@ihs.gov.
3. Questions on systems matters may
be directed to: Paul Gettys, Deputy
Director, Indian Health Service,
Division of Grants Management, 5600
Fishers Lane, Mail Stop: 09E70,
Rockville, MD 20857, Phone: (301) 443–
2114, email: Paul.Gettys@ihs.gov.
VIII. Other Information
The Public Health Service strongly
encourages all grant, cooperative
agreement, and contract recipients to
provide a smoke-free workplace and
promote the non-use of all tobacco
products. In addition, Public Law 103–
227, the Pro-Children Act of 1994,
prohibits smoking in certain facilities
(or in some cases, any portion of the
facility) in which regular or routine
education, library, day care, health care,
or early childhood development
services are provided to children. This
is consistent with the HHS mission to
protect and advance the physical and
mental health of the American people.
P. Benjamin Smith,
Deputy Director, Indian Health Service.
[FR Doc. 2022–26480 Filed 12–5–22; 8:45 am]
BILLING CODE 4165–16–P
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
74647
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Aging.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Aging.
Date: January 18–19, 2023.
Closed: January 18, 2023, 3:00 p.m. to 5:00
p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Open: January 19, 2023, 10:00 a.m. to 2:00
p.m.
Agenda: Call to order and report from the
Director; Discussion of future meeting dates;
Consideration of minutes of last meeting;
Reports from Task Force on Minority Aging
Research, Working Group on Program;
Council Speaker; Program Highlights.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Closed: January 19, 2023, 2:00 p.m. to 2:30
p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kenneth Santora, Director,
Office of Extramural Activities, National
Institute on Aging, National Institutes of
Health, Gateway Building, 7201 Wisconsin
Avenue, Bethesda, MD 20814, (301) 496–
9322, ksantora@nih.gov.
Information is also available on the
Institute’s/Center’s home page:
www.nia.nih.gov/about/naca, where an
E:\FR\FM\06DEN1.SGM
06DEN1
74648
Federal Register / Vol. 87, No. 233 / Tuesday, December 6, 2022 / Notices
Dated: November 30, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
[FR Doc. 2022–26431 Filed 12–5–22; 8:45 am]
Dated: December 1, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2022–26467 Filed 12–5–22; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Prospective Grant of an Exclusive
Patent License: Use and Development
of RAB13 and NET1 Targeting
Antisense Oligonucleotides in the
Treatment of Cancer
National Institutes of Health
AGENCY:
National Institute of General Medical
Sciences; Notice of Meeting
ACTION:
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of PRAT applications.
Date: March 7, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lee Warren Slice, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN12, Bethesda, MD
20892, 301–435–0807, slicelw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
VerDate Sep<11>2014
17:51 Dec 05, 2022
Jkt 259001
National Institutes of Health,
HHS.
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
U.S. Patents and Patent Applications
listed in the Supplementary Information
section of this notice to Drug
Development and Filing Consulting,
LLC located in Maryland, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before December 21, 2022 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Suna Gulay French,
Technology Transfer Manager,
Telephone: (240)-276–7424; Email:
suna.gulay@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
1. United States Provisional Patent
Application No. 62/966,204, filed
January 27, 2020 and entitled ‘‘RAB13
and NET1 Antisense Oligonucleotides
to Treat Metastatic Cancer’’ [HHS Ref.
No. E–041–2020–0–US–01];
2. PCT Patent Application No. PCT/
US2021/015053, filed January 26, 2021
and entitled ‘‘RAB13 and NET1
Antisense Oligonucleotides to Treat
Metastatic Cancer’’ [HHS Ref. No. E–
041–2020–0–PCT–02]; and
3. United States Patent Application
No. 17/792,507, filed July 13, 2022 and
entitled ‘‘Antisense Oligos that Block
Cancer Cell Migration and Invasion’’
[HHS Ref. No. E–041–2020–0–US–03].
PO 00000
Frm 00054
Fmt 4703
Sfmt 9990
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be the United States only
and the field of use may be limited to:
‘‘Use and development of RAB13 and
NET1 targeting antisense
oligonucleotides in treatment of breast
cancer, ovarian cancer, cervical cancer
and head and neck cancer in humans.’’
This technology discloses RAB13 and
NET1 targeting antisense
oligonucleotides (ASOs) for use in
targeted cancer therapy. These ASOs
bind to the 3′-untranslated regions of
RAB13 and NET1 mRNAs and prevent
the localization of these mRNAs to
cellular protrusions involved in
motility. These ASOs reduce cell
motility and migration in vitro. Due to
this reduction in cell motility and
migration, these ASOs are expected to
have uses in the treatment of metastatic
cancers.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 30, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2022–26430 Filed 12–5–22; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\06DEN1.SGM
06DEN1
]]>Agencies
[Federal Register Volume 87, Number 233 (Tuesday, December 6, 2022)]
[Notices]
[Pages 74647-74648]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26467]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Aging.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Aging.
Date: January 18-19, 2023.
Closed: January 18, 2023, 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).
Open: January 19, 2023, 10:00 a.m. to 2:00 p.m.
Agenda: Call to order and report from the Director; Discussion
of future meeting dates; Consideration of minutes of last meeting;
Reports from Task Force on Minority Aging Research, Working Group on
Program; Council Speaker; Program Highlights.
Place: National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).
Closed: January 19, 2023, 2:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kenneth Santora, Director, Office of Extramural
Activities, National Institute on Aging, National Institutes of
Health, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20814,
(301) 496-9322, [email protected].
Information is also available on the Institute's/Center's home
page: www.nia.nih.gov/about/naca, where an
[[Page 74648]]
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: December 1, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-26467 Filed 12-5-22; 8:45 am]
BILLING CODE 4140-01-P
